What your technology does. It only matter who uses it, whos the customer thats what i keep thinking. Today another sedate session, s p inched up. Nasdaq. 04 need a microscope here we keep learning this same lesson about technology over and over and over again in this elongated earnings season, and its pretty jarring, because normally we care about what technologies actually does, if its helpful, if it increases speed or accuracy or power or productivity, well, it tends to be a suchls. Buy, buy, buy if its clunky and dead on arrival sell, sell, sell not these days, though. These days wall street only cares about who your customers are. Good, bad, as long as youve got the right end markets, your stock is going to be worded. Lets use roku, okay, and cisco. Roku sells to the consumer, sells to you their Technology Helps you stream videos directly to your tv cisco is a networking company, a colossus that sells to what is known as the enterprise, giant complex companies that need to connect
Russell 2000 index that got our attention this evening the index hitting its own fresh 52week high are the small caps saying big things about the health of this record rally guy. Tim has talked about this and good for dan nathan. Why are you shaking your head . Why . Its monday. Were 30 seconds in. Youre already a downer. Dan mentioned it on the call. Everybody said dan is a downer hes not a downer, he pointed out the russell. 161. 5. That was the high back in may. These are pretty interesting levels the real high is at 173 that we traded back in august 2018 but the small caps are absolutely telling a story they have lagged the Broader Market for a while they seem to be catching up. The question is do we ratchet through this 161 level with the s p trading sideways for a while and retest that 173 high it certainly feels as though thats the next move so yes. Are you optimistic . I bring it up because its obvious. You look at this breakout here weve been looking at this index since the st
Biotech getting a bounce in the back of biogen two names you need to watch in the space. Halftime report starts right now. Welcome. Good to have you with us our Investment Committee today, joe, stephanie, josh, brynn is back lets begin with this big day for earnings stefrl dow stocks are moving this hour. Lets talk about some of those right there. Stephanie link, you go first mcdonalds is a drag comps below. They had the first eps miss in two years. Oh, my goodness, your sale completely out of this Company Earlier or later last week, whenever it was, looks good today. I actually thought it was going to be worse than what they put up today a 5. 9 global comp is impressive but the problem is they have to investment invest substantially to keep up with the competition. While i liked the story a while ago because of the Digital Initiatives and the ceo and all the things he has been doing they have to spend you dont get the operating leverage positively i was looking for. I got lucky, but i
China says unless you remove the december tariffs we dont have a deal otherwise. David dietze and kristen anderson, last but not least the wall street journal wealth reporter, veronica daguerre. David i will begin with you. One out of five s p 500 companies have already reported and 82 beating earnings estimates. 63 top line revenue estimates. So far, so good. What do you think . I generally agree with that. Remember the bar was set very, very low. Of course companies forced analysts to push down the ratings so it is easier to beat. Neil i thought i was only one who did that. Gave my parents d and fs and see cs would think i was genius. They learned from you. Expectations are very low. I am seeing pretty good beats. I like the fact revenue is coming up strongly. Remember that Information Technology sector that is really weighing down expectations for the s p 500. The rankandfile is doing extraordinarily well. Neil it is interesting, veronica, Biotech Sector on this stunning news out of
Our second panel will assess chinas role in Global Health and activities in the United States. We will start with rosemary gibson, introduce everybody first and then we will go to ms. Gibson. We will start with rosemary gibson, whose name has been mentioned already several times if you were here. Who is a Senior Advisor pasting Center Perspectives at the jama internal medicine. She is author china rx, exposing the risk ab next we will hear from ben westhoff an awardwinning investigative journalist mr. Westhoff new book retinol incorporated how roby chemists are creating the deadliest wave of the opioid epidemic. Will be published in september. The book focuses on that know with now kills more americans annually than any drug in american history. Our third panelist is jennifer buie who is a senior policy researcher and detained chair in china publicity stall is at the rain corporation. As an epidemiologist with training and clinical medicine and quantitative methods, doctor buie Researc